Are Local Drug Controls Depressing for the Pharmaceutical Industry?

By Gene J. Koprowski The makers of popular prescription pain killers oxycodone, alprazolam, and hydrocodone are facing a potential national decline in revenues if New York City Mayor ...

Cyclacel Explained: Answers About The Long Misunderstood And Undervalued Biotech

By Veziris Ventures Experience in biotech investing teaches us that it is a probability game if nothing else. As a company advances a drug candidate through clinical stages, the probability ...

ANGO and Microsulis Work Out Deal

By Zacks Equity Research Consolidating its earlier partnership, AngioDynamics (ANGO) inked a definitive agreement to purchase certain assets of Mircosulis Medical Ltd. The transaction ...

Robert Funari Joins NxStage Board of Directors

By  NxStage Medical, Inc. LAWRENCE, Mass., /PRNewswire/ — NxStage®Medical, Inc. (NXTM), a leading manufacturer of innovative dialysis products, today announced that Robert ...

Intuitive Surgical’s Fourth Quarter Reveals Continued Strength

By Valuentum After reports from short sellers claimed growth was slowing at Intuitive Surgical (ISRG), the company’s fourth-quarter performance provided evidence to the contrary. ...

St Jude Medical Earnings Call Nuggets: the FDA Warning Letter and This Year’s Guidance Approach

By Alexandra Leigh St Jude Medical, Inc. (NYSE:STJ) recently reported its fourth quarter earnings and discussed the following topics in its earnings conference call. The FDA Warning ...

ReCor Medical snags CE mark for next-gen renal denervation

By Damian Garde Now that Boston Scientific ($BSX) has purchased Vessix Vascular, California’s ReCor Medical is the only privately held company with a CE marked renal denervation device. ...

Grassley Presses NSF For Conflicts Of Interest Plan

By Ed Silverman In 2011, the National Science Foundation was told by its own Office of Inspector General that its policy for overseeing and managing conflicts involving researchers ...

Herceptin Pricing In India Is A Joke: Menon Explains

By Ed Silverman Last week, the Indian government moved closer to issuing compulsory licenses on three widely used cancer medications – including Roche’s Herceptin – in hopes of ...

Bill Would Repeal The Amgen Gift From Washington

By Ed Silverman Following disclosure that the recently passed ‘fiscal cliff’ bill delays Medicare price restraints on a group of medications that will benefit Amgen while costing ...

Roche’s Avastin gets another indication approval

Genentech team notches another big win for its parent By Eric Palmer Chalk up another big win for Hal Barron and his R&D team extraordinaire at Genentech. The FDA today approved ...

UPDATED: Bristol-Myers finds silver (tax) lining after Hep C disaster

By Ryan McBride Bristol-Myers Squibb watched its coveted hepatitis C drug 094 go down the drain last year after discovering safety hazards in a midstage study. Yet the pharma giant ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS